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Key Points
• Platelets expressing a
talin 1 mutant (R35E)
that significantly
reduces Rap1 affinity
exhibit little change in
GPIIb-IIIa activation.
• Tln1R35E/R35E mice are
viable, apparently
healthy, and fertile, with
similar bleeding times
as wild-type littermates.
Activation of platelet glycoprotein IIb-IIIa (GPIIb-IIIa; integrin aIIbb3) leads to high-aﬃnity
ﬁbrinogen binding and platelet aggregation during hemostasis. Whereas GTP-bound Rap1
GTPase promotes talin 1 binding to the b3 cytoplasmic domain to activate platelet GPIIb-IIIa,
the Rap1 effector that regulates talin association with b3 in platelets is unknown. Rap1
binding to the talin 1 F0 subdomain was proposed to forge the talin 1–Rap1 link in platelets.
Here, we report a talin 1 point mutant (R35E) that signiﬁcantly reduces Rap1 aﬃnity without
a signiﬁcant effect on its structure or expression. Talin 1 head domain (THD) (R35E) was of
similar potency to wild-type THD in activating aIIbb3 in Chinese hamster ovary cells.
Coexpression with activated Rap1b increased activation, and coexpression with Rap1GAP1
reduced activation caused by transfection of wild-type THD or THD(R35E). Furthermore,
platelets from Tln1R35E/R35E mice showed similar GPIIb-IIIa activation to those from wild-
type littermates in response to multiple agonists. Tln1R35E/R35E platelets exhibited slightly
reduced platelet aggregation in response to low doses of agonists; however, there was not a
signiﬁcant hemostatic defect, as judged by tail bleeding times. Thus, the Rap1–talin 1 F0
interaction has little effect on platelet GPIIb-IIIa activation and hemostasis and cannot
account for the dramatic effects of loss of Rap1 activity on these platelet functions.
Introduction
Platelet aggregation, which is essential for normal hemostasis,1 is initiated by agonists, such as thrombin or
collagen, resulting in activation of glycoprotein IIb-IIIa (GPIIb-IIIa; integrin aIIbb3) to bind fibrinogen with high
affinity.2GPIIb-IIIa activation depends on binding of talin 1 to the integrin b3 cytoplasmic tail.3Rap1GTPases
are important intermediaries in integrin activation. In particular, mice deficient in Rap1b, the most abundant
isoform of Rap1 in platelets, or its main activator CalDAG-GEF1, exhibit impaired GPIIb-IIIa activation.4,5
Moreover, platelet-specific deletion of Rap1a and Rap1b leads to a profound defect in GPIIb-IIIa activation
and hemostasis.6 RIAM is a Rap1 effector that recruits talin 1 to integrin aIIbb3 in a model nonhematopoietic
system.7-9 However, genetic ablation of RIAM in mice does not affect hemostasis or GPIIb-IIIa activation,
indicating that it is not the relevant Rap1 effector in platelets.10-12
The N-terminal talin 1 head domain (THD) is an atypical FERM domain with an F0 domain, in addition to the 3
characteristic subdomains (F1, F2, F3). The structure of the F0 domain resembles that of the Ras-
association domain in RalGDS, and Rap1 binds weakly to talin 1 F0 (dissociation constant [Kd];140 mM)
in a guanosine triphosphate–dependent manner.13 In Dictyostelium, Rap1 binds to the Ras-association
domain of talinB to mediate cellular adhesion during morphogenesis.14 The low-affinity binding of talin 1 F0 to
Rap1 was confirmed by a recent study that suggested that this was the Rap1–talin 1 interaction that
mediates platelet GPIIb-IIIa activation.15 Here, we analyzed the effect of F0 mutations that disrupt Rap1
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binding on the ability of THD to activate integrin aIIbb3 in a CHO cell
system. These mutations did not affect aIIbb3 activation, nor did they
alter the effect of manipulation of Rap1 activity on aIIbb3 activation.
We generated Tln1R35E/R35E mice harboring a mutation that
significantly reduces the affinity of talin 1 F0 for Rap1. Initial platelet
GPIIb-IIIa activation and hemostasis were similar in Tln1R35E/R35E
mice and wild-type littermates; however, platelet aggregation in
response to low doses of agonists was reduced. Thus, Rap1 binding
to talin 1 F0 cannot account for the dramatic effects of the loss of
Rap1 activity on GPIIb-IIIa activation and hemostasis.
Methods
Reagents
Prostacyclin (PGI2), adenosine 59-diphosphate, thrombin, and calcium
ionophore A23187 were from Sigma-Aldrich. Protease-activated
receptor 4–activating peptide (PAR4-AP, AYPGKF-NH2) was from
GenScript. Cross-linked collagen-related peptide (CRP-XL) was from
the University of Cambridge (Department of Biochemistry). Fibrillar
collagen type I was from Chrono-log. U46619 was from Cayman
Chemical.
Protein expression and purification
The murine talin 1 residues 1-85 (F0) were cloned into the expression
vector pETM-11 (His-tagged, EMBL) and expressed inEscherichia coli
BL21 Star (DE3) cultured in minimal medium for 15N-labeled samples
for nuclear magnetic resonance (NMR). Briefly, recombinant His-
tagged F0 was purified by nickel-affinity chromatography, the His-tag
was removed by cleavage with Tobacco Etch Virus protease overnight,
and the protein was further purified by size-exclusion chromatography
using a Superdex 75 (26/600) column (GE Healthcare). The column
was pre-equilibrated and run with (NMR buffer) 20 mM sodium
phosphate, 50 mM NaCl, 3 mM MgCl2, 2 mM dithiothreitol, pH 6.5.
Human Rap1 isoform Rap1b (residues 1-167) cloned into pTAC vector
in the E coli strain CK600K was the generous gift of Professor
Alfred Wittinghofer (Max Planck Institute of Molecular Physiology,
Dortmund, Germany). Untagged Rap1b was purified by ion exchange,
followed by Superdex 75 (26/600) gel filtration, as previously de-
scribed.16 The column was pre-equilibrated and run with NMR buffer.
NMR titration
Titration curves for the interaction of talin 1 F0 with GMP.PNP-bound
Rap1b were determined using 100 mM 15N-labeled F0 in NMR buffer
containing 5% (v/v) 2H2O. All 2-dimensional (2D) [
1H,15N]-sfHMQC
spectra were recorded at 298 K. Chemical shift changes [Ddobs (HN,N)]
were calculated usingCcpNmr Analysis “follow shift changes” function
and analyzed with the 1-site binding model to determine the Kd value in
Prism 5.0 (GraphPad Software).17
Integrin activation in Chinese hamster ovary cells
Cells were cultured in Dulbecco’s modified Eagle medium (Corning)
supplemented with 10% fetal bovine serum (Sigma-Aldrich),
100 U/mL penicillin, and 100 mg/mL streptomycin (Gibco). The
sequence encoding murine THD (amino acids 1-433) was cloned into
pEGFP-N1 (Clontech). Point mutations were incorporated by PCR
using gBlocks gene fragment (IDT) as templates. The sequences
encoding human Rap1b(Q63E) and Rap1GAP1 were cloned into
pDsRed-Monomer-C1 (Clontech). Transient transfection was per-
formed using TransIT-LT1 Transfection Reagent (Mirus), according to
the manufacturer’s protocol. PAC-1 binding assay was conducted as
previously described.18Briefly, cells were harvested using trypsin 1 day
after transfection and washed once in Hanks balanced salt solution
buffer (containing calcium and magnesium; Gibco) supplemented
with 1% (w/v) bovine serum albumin (BSA; Sigma-Aldrich). PAC-1
immunoglobulin M (ascites, 1:200) was incubated with cells for 30
minutes at room temperature prior to staining with the appropriate
Alexa Fluor 647 secondary antibody (Life Technologies) for 30minutes
on ice. Cells were analyzed by flow cytometry using a FACSAria (BD
Biosciences) and gated on double EGFP/DsRed1 events. Integrin
activation was defined as aIIbb3-specific ligand binding corrected for
aIIbb3 expression and was calculated as 100 3 (MFIi 2 MFI0)/
DMFID57 (MFIi 5 mean fluorescence intensity [MFI] of bound PAC-1,
MFI05 mean fluorescence intensity of bound PAC-1 in the presence
of 10 mM eptifibatide, and DMFID57 5 specific fluorescence intensity
of anti-aIIbb3 D57 antibody). PAC119 and D5720 antibodies have
been previously described.
Mice
Tln1R35E/R35E mice were generated by the CRISPR/Cas9 approach at
the University of California Irvine Transgenic Mouse Facility (UCI TMF).
Apbb1ip2/210,12 and Tln22/221 mice have been described. Eight- to
16-week-old sex-matched wild-type littermates were used as control
animals for all experiments. Tln1R35E/R35E knock-in mice were generated
using aCRISPR/Cas9 approach at the UCI TMF. The single guide RNA
and the single-stranded oligonucleotides were from IDT. Cas9 mRNA/
single guide RNA/tracRNA (3 mM) was mixed with single-stranded
oligonucleotides (5 ng/mL) and injected into the pronuclei of B6SJLF2
embryos. Surviving embryos were implanted into ICR pseudopregnant
females, and pregnancies went to full term. Tissue biopsies for genomic
DNA were taken from pups between 7 and 10 days. Mice were
genotyped by polymerase chain reaction using forward primer 59-
gtattctaatgctctgatgctactggc-39 and reverse primer 59-aaagtcgttggc-
taaaagagatggtag-39, followed by Sanger sequencing. Three founder
Tln1R35E/R35E mice were backcrossed to a C57BL/6 strain to obtain
heterozygous Tln1wt/R35E mice. We used sex-matched Tln1wt/wt
littermates as controls for Tln1R35E/R35E mutant animals in all
experiments. Mice were housed in the animal facilities of the University
of California, San Diego. Experimental procedures were approved by
the Institutional Care and Use Committee.
Blood counts
Peripheral blood was collected from the retro-orbital plexus and
transferred to tubes containing EDTA. Cell counts were performed
using a Hemavet 950FS hematology system programmed with
mouse-specific settings (Drew Scientific). All samples were tested
in duplicate, and the mean for each animal was plotted.
Platelet preparation
Blood was drawn with heparin-coated capillaries (VWR) from the
retro-orbital plexus into tubes containing low-molecular-weight
LOVENOX (enoxaparin sodium; Sanofi-Aventis). Whole blood was
diluted with modified Tyrode’s buffer (137 mMNaCl, 0.3 mMNa2HPO4,
2 mM KCl, 12 mM NaHCO3, 5 mM N-2-hydroxyethylpiperazine-N9-2-
ethanesulfonic acid, 5 mM glucose, pH 7.3) containing 0.35%BSA.
Platelet-rich plasma (PRP) was obtained by 2 successive centrifu-
gation steps at 130g for 4 minutes and then at 100g for 5 minutes
at room temperature. PRP was centrifuged at 700g for 5 minutes
at room temperature in the presence of 5 mM PGI2 to pellet
platelets. Platelets were resuspended in modified Tyrode’s buffer,
and platelet concentration was adjusted to 5 3 108/mL.
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Flow cytometry
Washed platelets were diluted to 4 3 107/mL in Tyrode’s solution
containing 1 mM CaCl2 with agonists in the presence of fibrinogen
conjugated to Alexa Fluor 488 (150 mg/mL; Life Technologies).
After 10 minutes of incubation, each sample was further diluted
1:40 in phosphate buffered saline (PBS) and analyzed immediately
with a BD Accuri C6 Plus flow cytometer (BD Biosciences).
For whole-blood assays, blood was diluted 1:12.5 in modified
Tyrode’s solution containing 1 mM CaCl2 with agonists in the
presence of Jon/A-phycoerythrin (PE) (2 mg/mL) and GPIX labeled
with Alexa Fluor 647 (2 mg/mL), incubated for 10 minutes at room
temperature, and diluted 1:400 in PBS prior to fluorescence-
activated cell sorting. For real-time GPIIb-IIIa activation assay,
washed platelets were diluted in modified Tyrode’s solution
containing 1 mMCaCl2. After establishing a baseline with unlabeled
platelets for 30 seconds, Jon/A-PE and PAR4-AP agonist were
added simultaneously in an equal volume of modified Tyrode’s
solution. Jon/A-PE binding was recorded continuously for 10 minutes.
Monoclonal antibodies directed against GPIX (Xia.B4) or activated
murine GPIIb-IIIa (Jon/A-PE) were from emfret Analytics. For sur-
face receptor analysis, 2 3 106 platelets in diluted whole blood
(modified Tyrode’s buffer) were stained for 10 minutes with 2 mg/mL
fluorophore-conjugated antibodies and immediately analyzed by
flow cytometry. PE-conjugated antibodies against CD41 (MWReg30;
control isotype RTK2071) and CD61 (2C9.G2; control isotype
HTK888)were fromBioLegend. Fluorescein isothiocyanate–conjugated
antibody against P-selectin (CD62P, RB40.34; control isotype A110-1)
was from BD Biosciences.
Aggregometry
PRP was diluted to a concentration of 2 3 108 platelets/mL in
modified Tyrode’s buffer containing 0.35% BSA and 1 mM CaCl2.
The experiment was performed at 37°C under stirring conditions
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Figure 1. Biochemical characterization of the talin 1 R35E mutation to block binding to Rap1b. (A) Surface electrostatic potential of talin 1 F0 (left panel) and
Rap1b (right panel) binding interface as open book view. The charge complementarity between the 2 proteins’ binding interface is represented by the dashed line. (B-E) 2D
NMR 1H,15N-sfHMQC spectra (298K, 600 MHz) of 100 mM 15N-labeled talin 1 F0. (B) Free talin 1 F0 wild-type (blue) and R35E (red). Almost all peaks are in the same position,
suggesting that THD(R35E) is well folded and has a fold similar to wild-type protein. (C) Talin 1 F0 wild-type (blue); with sevenfold excess Rap1b (red), specific chemical shift changes
are observed and indicated by arrows. (D) Close-up view of the 10-step Rap1b titration for residues G11 and A41. (E) Talin 1 F0(R35E) (blue); in the presence of sevenfold excess
Rap1b (red), minimal chemical shift changes are observed, showing that THD(R35E) drastically reduced interaction. (F) Titration curves for the interaction of talin 1 F0 wild-type (blue)
or R35E (red) (100 mM) with increasing amounts of Rap1b (0-700 mM). Wild-type dissociation constants were measured for multiple residues, and binding curves are shown for G11
and G42 talin 1 F0 wild-type and mutant proteins. The F0(R35E) affinity for Rap1b was dramatically reduced (at 700 mM Rap1b, no binding was detected).
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of PAR4-AP. Light transmission was recorded on a Chrono-log
4-channel optical aggregation system (Chrono-log).
Tail bleeding time assay
Mice were anesthetized, and a 5-mm segment of the tail tip was cut
off with a scalpel. The tail was immediately immersed in isotonic
saline prewarmed to 37°C. Bleeding times were the time required
for bleeding to cease for $60 seconds.
Platelet static adhesion to fibrinogen
Glass coverslips were coated with 100 mg/mL fibrinogen (Sigma-
Aldrich) in PBS for 1 to 2 hours at 37°C, washed twice with PBS, and
blockedwith 5%BSA/PBS for 2 hours at 37°C.Washed platelets were
diluted 1:10 in Tyrode’s solution containing 1mMCaCl2 in the presence
of 0.01 U/mL thrombin and left to adhere to fibrinogen-coated glass
coverslips for various times. Wells were washed 3 times with Tyrode’s
solution. Adherent platelets were fixed with formaldehyde, stained with
Alexa Fluor 488 phalloidin (Life Technologies), and imaged using an
LSM 880 with Airyscan confocal microscope (633/1.4 oil objective;
Carl Zeiss). The number of attached platelets and the spreading area
were measured using the ImageJ image analysis software.
Western blotting
Washed platelets were pelleted by centrifugation at 700g for 5
minutes at room temperature and then lysed in Laemmli sample
buffer. Lysates were subjected to 4% to 20%–gradient sodium
dodecyl sulfate–polyacrylamide gel electrophoresis. For analysis of
talin levels, platelet lysates were subjected to 6% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis for better protein
separation. Antibodies directed against talin 1 (93E12) and talin 2
(68E7) were from Novus Biologicals. Anti-Rap1A/B was from Cell






















































































































Figure 2. Talin 1 R35E mutation does not impede aIIbb3 integrin activation in CHO cells. (A) CHO-A5 cells stably expressing aIIbb3 integrin were transfected with
complementary DNA encoding EGFP-tagged THD in combination with Rap1b(Q63E) or Rap1GAP1. Integrin activation was assayed by binding of PAC1 to EGFP1 cells. Bar
graph shows mean 6 standard error of the mean (SEM) of 4 independent experiments. No significant differences between wild-type and mutants were detected. (B) Activation
indices were normalized to the maximum value of THD(wild-type)–EGFP and plotted as a function of EGFP-MFI. Graphs represent mean 6 SEM of 4 independent experiments.
Curve fitting was performed using the total 1 site-binding model in Prism 5.0 (GraphPad Software). No significant difference between wild-type and mutants was detected.
(C) Expression of EGFP-THD mutants was assayed by western blotting. *P , .05, **P , .01, ***P , .001, 2-way analysis of variance with Bonferroni posttest.
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Figure 3. Platelets expressing talin 1(R35E) exhibit normal GPIIb-IIIa integrin activation. (A) Generation of mice expressing talin 1(R35E) mutant. (B) Sequencing
chromatogram of the mutated region of Tln1(R35E) gene. (C) Expression of talin 1(R35E) mutant in platelets was assayed by western blotting. Results are representative of 3
independent experiments, n 5 3 mice each time. (D-F) Normal GPIIb-IIIa integrin activation in Tln1R35E/R35E platelets. (D) Real-time GPIIb-IIIa activation assay. Jon/A-PE binding
to washed platelets was recorded continuously for 10 minutes by flow cytometry. Jon/A antibody was added at the time of stimulation with 75 or 500 mM PAR4-AP (indicated
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and b-actin (AC-15) were from Sigma-Aldrich. The appropri-
ate IRDye/Alexa Fluor–coupled secondary antibodies were from
LI-COR. Nitrocellulose membranes were scanned using an
Odyssey CLx Infrared Imaging System, and blots were processed
using Image Studio Lite software (both from LI-COR).
Statistics
Statistical significance was assayed by a 2-tailed Student t test for
single comparisons or analysis of variance for multiple comparisons
with a Bonferroni post hoc test. P , .05 was considered significant.
Results
Reduced affinity of talin 1(R35E) F0 domain binding
to Rap1
Our molecular modeling and a published NMR structure15
suggested that talin 1 Lys15 and Arg35 formed crucial salt bridges
with an acidic patch on Rap1b (Figure 1A). We prepared K15E
and R35E mutants of F0 and noted that the R35E mutant was
more stable when expressed in bacteria. Comparison of the NMR
2D-sfHMQCof the F0wild-type andR35Emutant (Figure 1B) showed
Figure 3. (continued) by the arrow). Flow cytometry assay to measure binding of GPIX-labeled platelets in whole blood to Jon/A antibody (E) or washed platelets to
fibrinogen (F) in response to agonist stimulation. Alexa Fluor 488–coupled fibrinogen and Jon/A-PE were added simultaneously with agonists for 10 minutes. Bar graphs
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Figure 4. Unstable aggregation of Tln1R35E/R35E platelets in response to stimulation with a low dose of agonists. Aggregation of Tln1wt/wt and Tln1R35E/R35E
platelets stimulated with various doses of PAR4-AP (A), fibrillar collagen type I (B), and the thromboxane A2 analog U46619 (C). Arrows indicate addition of the agonist.
Results are representative of 3 independent experiments, n 5 3 mice each time.
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only very subtle chemical shift changes; thus, the mutant protein
adopts a similar fold to wild-type F0. Addition of GMP.PNP Rap1b
to F0 produced specific chemical shift changes detectable at
25 mM GMP.PNP Rap1b (Figure 1C-D,F), whereas addition of
GMP.PNP Rap1b to F0(R35E) produced almost none at 700 mM
GMP.PNP Rap1b (Figure 1E-F). Furthermore, we mapped specific
chemical shifts to amino acids located in the predicted binding
interface, including Lys15 and Arg35. NMR titrations, based on the
fitting of chemical shift perturbations of amino acids located at the
binding interface, showed a weak affinity of talin 1 F0 for Rap1b.
Based on this standard method of NMR titration,15 we calculated
Kd 5 196 6 68 mM (Figure 1F, blue lines). The minimal chemical
shift perturbations detected in talin 1 F0(R35E) at 700 mM Rap1b
(sevenfold excess) precluded calculation of Kd, but it did indicate
a dramatic reduction in Rap1b affinity (Figure 1F). Thus, talin 1
F0(R35E) is well folded and binds to activated Rap1b with greatly
reduced affinity.
Talin 1 F0–Rap1b interaction is dispensable for
THD-mediated aIIbb3 activation in CHO cells
To assess the contribution of the talin 1 F0 interaction with Rap1 on
integrin activation, we introduced the mutations K15E and/or R35E
into the THD and tested effects on integrin activation in Chinese
hamster ovary (CHO) A5 cells stably expressing human aIIbb3.
Expression of wild-type THD induced activation (Figure 2A). Expres-
sion of the constitutively activated Rap1b(E63) mutant, which is
unable to form the Rap1-Rap1GAP1 complex,22 increased wild-type
THD-mediated aIIbb3 activation. Inhibition of endogenous Rap1
activity by coexpression of Rap1GAP1 led to a decrease in THD-
mediated activation (Figure 2A). THD(K15E), THD(R35E), or THD
(K15E,R35E) mutants were similar to wild-type THD in activating
aIIbb3 and in the effect of manipulating Rap1 activity (Figure 2A).
Furthermore, we carefully monitored expression of THD-EGFP and its
mutants in each cell by flow cytometry and observed no differences in
their capacity to activate aIIbb3, regardless of their abundance
(Figure 2B). Immunoblotting confirmed a similar level of expression
for all THD mutants (Figure 2C).
Generation of Tln1R35E knock-in mice
A striking feature of platelets is the abundance of Rap1b and talin 1,
with ;220 000 molecules per platelet.23 Hence, the low-affinity
talin 1–Rap1b interaction could regulate GPIIb-IIIa in platelets. To
test this hypothesis, we usedCRISPR/Cas9 to generate Tln1R35E/R35E
mice (Figure 3A-B). Homozygous Tln1R35E/R35E mice were viable
and fertile and exhibited no gross developmental abnormalities,
with normal platelet and blood cell counts (supplemental
Figure 1). Platelet content of talin 1, Rap1b (Figure 3C), and surface
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Figure 5. Analysis of platelet adhesion and secretion, as well as hemostasis, in Tln1R35E/R35E mice. (A) P-selectin (CD62P) surface expression onto platelets in
whole blood. Bar graph represents DMFI 6 SEM (n 5 4 mice, representative of 2 independent experiments). (B-C) Adhesion of Tln1R35E/R35E platelets onto fibrinogen-coated
surfaces. Washed platelets were stimulated with thrombin (0.01 U/mL). Platelets were pooled from 3 mice, 2 independent experiments. (B) Bar graphs are mean 6 SEM of
adhered platelet counts at the indicated time points after stimulation. (C) Quantification of platelet area at 45 minutes. Data are mean 6 SEM. (D) Tail bleeding analysis.
The experiment was terminated at the end of 10 minutes to avoid excessive loss of blood. No significant differences were observed between Tln1wt/wt mice (n 5 15)
and Tln1R35E/R35E mice (n 5 14).
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mice. Thus, Tln1R35E/R35E mice are suitable for examining the
effects of blocking Rap1 binding to the talin 1 F0 domain on platelet
integrin function in vivo and ex vivo.
Normal agonist-induced GPIIb-IIIa activation of
Tln1R35E/R35E platelets
We evaluated activation of GPIIb-IIIa in response to stimulation with
PAR4 agonist-peptide (PAR4-AP) by measuring real-time binding
of Jon/A24 to washed platelets and observed that Jon/A bound
to PAR4-AP–activated Tln1R35E/R35E platelet GPIIb-IIIa with similar
kinetics and to a similar extent as wild-type platelets (Figure 3D).
To rule out a platelet-washing artifact, we assessed GPIIb-IIIa
activation in whole blood using Jon/A and found that multiple
agonists stimulated Jon/A binding to Tln1R35E/R35E platelets
indistinguishably from wild-type platelets (Figure 3E). As a second
measure of GPIIb-IIIa activation, we assessed fibrinogen binding to
washed platelets and found that binding to Tln1R35E/R35E platelets
stimulated with PAR-AP, adenosine 59-diphosphate, ionophore
A23187, or collagen-related peptide was similar to fibrinogen
binding to platelets from wild-type mice (Figure 3F). Thus, these
data indicate that Rap1 binding to talin 1 F0 domain is dispensable
for GPIIb-IIIa activation in platelets.
Mild defect in aggregation of Tln1R35E/R35E platelets
To examine the ability of Tln1R35E/R35E platelets to form aggregates,
we stimulated diluted PRP in a standard optical aggregometer with
various doses of PAR4-AP, collagen, or the thromboxane A2 analog
U46619. There was a consistent reduction in the ability of low doses
of agonists to induce Tln1R35E/R35E platelet aggregation (Figure 4).
Surface expression of P-selectin in Tln1R35E/R35E platelets was
similar to platelets from wild-type mice (Figure 5A), indicating no
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Figure 6. GPIIb-IIIa activation in Tln1R35E/R35E ,
Apbb1ipKO/KO (RIAM-null) platelets. (A) Western blot
analysis of talin 1 and RIAM expression in platelets. Vinculin
was used as a loading control. (B-C) Normal GPIIb-IIIa integrin
activation in Tln1R35E/R35E, Apbb1ip2/2 platelets. Flow cytom-
etry assay to measure binding of washed platelets to fibrinogen
(B) or GPIX-labeled platelets in whole blood to Jon/A antibody
(C). Bar graphs represent MFI 6 SEM (n 5 4 mice,
representative of 2 independent experiments).
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of GPIIb-IIIa function in Tln1R35E/R35E platelets, we quantified platelet
adhesion and spreading on fibrinogen-coated coverslips in re-
sponse to stimulation with thrombin. There was no difference in the
number of adhered platelets (Figure 5B). Tln1R35E/R35E platelets
spread and extend lamellipodia to a similar extent as wild-type
platelets (Figure 5C). Importantly, there was a slight, but insignif-
icant, prolongation of tail bleeding times in Tln1R35E/R35E mice
(Figure 5D), indicating largely intact hemostasis. Together, these data
confirm that the activation and hemostatic functions of GPIIb-IIIa are
largely intact in Tln1R35E/R35E platelets.
Tln1R35E/R35E mutation is not compensated by
RIAM or talin 2
Platelets express little RIAM.10,15,23 However, it is possible that
upregulation of RIAM bridges Rap1 to talin 1(R35E), thereby
compensating for the blockade of the direct Rap1/talin 1 interaction.
Tln1R35E/R35E platelets exhibited no increase in RIAM expression.
Platelets from Tln1R35E/R35E-Apbb1ip2/2 mice, lacking RIAM,
exhibited normal GPIIb-IIIa activation (Figure 6). These data exclude
a compensatory role for RIAM. Furthermore, we examined whether
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Figure 7. GPIIb-IIIa activation in Tln1R35E/R35E , Tln22/2
platelets. (A) Western blot analysis of talin 1 and talin 2
expression in platelets and heart. Vinculin was used as a loading
control. Talin 2 is not expressed in platelets. (B-C) Normal
GPIIb-IIIa integrin activation in Tln1R35E/R35E, Tln22/2 platelets.
Flow cytometry assay to measure binding of washed platelets to
fibrinogen (B) or GPIX-labeled platelets in whole blood to Jon/A
antibody (C). Bar graphs represent MFI 6 SEM (n 5 3 mice,
representative of 2 independent experiments).
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the Tln1R35E/R35Emutation. We could not detect talin 2 expression in
platelets, confirming previous reports,25,26 and its expression was not
increased in response to the Tln1R35E/R35E mutation (Figure 7).
Furthermore, initial GPIIb-IIIa activation in Tln1R35E/R35E;Tln22/2
platelets was indistinguishable from control Tln1wt/wt;Tln21/1 plate-
lets (Figure 7).
Discussion
Rap1 GTPases play a critical role in triggering talin-mediated platelet
GPIIb-IIIa activation. Our studies have critically examined the role of the
binding of Rap1 to the talin 1 F0 domain,13which has been proposed15
to account for the link between Rap1 and talin. Using the structure of
the Rap1-F0 complex, we created a single F0 point mutant that did not
alter F0 folding and documented that it significantly reduced the affinity
of the interaction. Using the well-established CHO system, we showed
that this mutation did not affect the capacity of THD to activate
recombinant aIIbb3 across a wide range of expression of THD, nor did
it alter the effects of manipulating Rap1 activity. To directly test the role
of the Rap1–F0 interaction, we generated Tln1R35E/R35E mice and
observed negligible effects on GPIIb-IIIa activation by a wide variety of
agonists and on resulting hemostasis; however, we observed a mild
defect in platelet aggregation. In sum, our studies show that the talin 1
F0–Rap1 interaction makes a minor contribution to the capacity of
Rap1 to trigger GPIIb-IIIa activation and resulting hemostasis.
The interaction of talin 1-F0 with Rap1b plays no evident role
in THD-induced recombinant aIIbb3 activation in CHO cells.
These cells, termed A5 cells,27 have come into wide use and
were instrumental in showing the role of THD in activation28 and
how RIAM linked Rap1 to talin to activate integrins.7 Indeed, when
Goult et al13 first reported the Rap1–F0 interaction, we tested a
series of mutants predicted to block the interaction, with no effect
on aIIbb3 activation. In repeating these experiments, with careful
quantification of THD expression on a per-cell basis by flow cytometry,
we have confirmed our earlier results (Figure 2B). A recent study15
reported conflicting results; however, differences in experimental
methods should be noted. In particular, that study used a THD
(K15A,R35A) double mutant. We used the acidic Glu mutations
because of the predicted stronger effects of charge repulsions
between talin 1 F0 and the acidic patch on the surface of Rap1b
that mediates their interaction (Figure 1A). Secondly, we carefully
monitored the folding of the R35E mutant (Figure 1B), which was
a particular concern in light of the instability of the K15E mutant in
our hands. This concern also led to a careful assessment of the
expression of mutant and wild-type THD (Figure 2B-C), a feature
notably absent from the study by Zhu et al.15 Thus, in A5 cells, a
mutant that drastically reduces the Rap1-F0 affinity has little effect
on the capacity of THD to activate recombinant aIIbb3.
The talin 1(R35E) mutant has little effect on platelet GPIIb-IIIa
activation or hemostasis. In the present study, we did not observe any
consistent effect of Tln1(R35E) on GPIIb-IIIa activation by several
agonists that use distinct receptors in washed platelets, as assessed
by the binding of fibrinogen or Jon/A, or in whole blood by Jon/A
binding. These results were confirmed by the minor effects on platelet
aggregation and bleeding time and are in striking contrast to the
profound effects of loss of Rap1 activity6 or talin 126,29 or of mutations
of b3 that block talin binding.30 Importantly, our studies definitively
exclude the possibility that upregulation of talin 2 or RIAM expression
could account for the lack of effect of this mutation. The mild defect in
platelet aggregation at low doses of agonist, in the presence of intact
GPIIb-IIIa activation, suggests that the talin 1 F0–Rap1 interaction
helps to stabilize the capacity of the platelet aggregates to resist the
shear forces in the platelet aggregometer; hence, future studies to
explore whether this mild aggregation defect confers an antithrom-
botic benefit seem warranted.
What is the nature of the Rap1 effector that controls talin 1-
dependent integrin activation in platelets? Clearly, F0 binds Rap1
with low affinity and, in Dictyostelium, appears to have an important
functional role.13-15 The extraordinary abundance of Rap1 and talin 1 in
platelets and the absence of any stoichiometrically reasonable Rap1
effector23 provided a compelling rationale for considering talin 1 F0 as
the logical Rap1 effector15; however, our results seem to preclude this
idea and leave this critical question open. Zhu et al’s comprehensive
study reported that Rap1 interaction with talin 1 F1 or kindlin2 F0 could
not be detected,15 appearing to rule out these likely candidates. Vinculin
interaction with talin 1 can lead to talin 1–integrin interaction and
integrin activation31; however, vinculin-null platelets exhibit no
reduction in GPIIb-IIIa activation,32 and vinculin-RIAM double-knockout
platelets also exhibit no such defect (Brian G. Petrich and M.H.G.,
unpublished observations). Thus, future studies could be directed at
the possibility that Rap1 can influence the talin 1–integrin interaction by
triggering a catalytic event that results in a change of membrane lipid
composition or a posttranslational modification of talin 1. The present
work would exclude the Rap1–talin 1 F0 interaction as playing a critical
role in GPIIb-IIIa activation.
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